摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(3,4-dihydroxyphenyl)-8H-thieno[2,3-b]pyrrolizin-8-one

中文名称
——
中文别名
——
英文名称
3-(3,4-dihydroxyphenyl)-8H-thieno[2,3-b]pyrrolizin-8-one
英文别名
3-(3,4-Dihydroxyphenyl)-8H-thieno[2,3-b]pyrrolidine-8-one;3-(3,4-dihydroxyphenyl)thieno[2,3-b]pyrrolizin-8-one
3-(3,4-dihydroxyphenyl)-8H-thieno[2,3-b]pyrrolizin-8-one化学式
CAS
——
化学式
C15H9NO3S
mdl
——
分子量
283.307
InChiKey
ZJGDMPPPYUACSI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    20
  • 可旋转键数:
    1
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    90.7
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    丁酸酐3-(3,4-dihydroxyphenyl)-8H-thieno[2,3-b]pyrrolizin-8-one 作用下, 以 sodium hydroxide 为溶剂, 反应 1.0h, 生成 2-(Butyryloxy)-4-(8-oxo-8H-thieno[2,3-b]pyrrolizin-3-yl)phenyl butyrate
    参考文献:
    名称:
    8H-thieno-[2,3-b]pyrrolizin-8-one compounds
    摘要:
    公式(I)中选择的化合物:##STR1## 其中:R.sub.1代表氢,卤素,烷基,硝基,羟基,烷氧基,三卤代烷基,三卤代烷氧基或可选取代氨基,R.sub.2代表可选取代的芳基或杂环基,R.sub.3代表氢,卤素,烷基,硝基,羟基,烷氧基,三卤代烷基,三卤代烷氧基或可选取代氨基,它们的异构体和药学上可接受的酸或碱盐以及含有它们的药物制品在癌症治疗中有用。
    公开号:
    US06071945A1
  • 作为产物:
    参考文献:
    名称:
    Design, Synthesis, and Evaluation of Novel Thienopyrrolizinones as Antitubulin Agents
    摘要:
    Herein, we describe the structure-activity relationship study of a new 3-aryl-8H-thieno[2,3-b]pyrrolizin-8-one series of antitubulin agents. The pharmacological results from the National Cancer Institute in vitro human disease oriented tumor cell line screening allowed us to identify compound 1d (NSC 676693) as a very efficient antitumoral drug in all cancer cell lines tested. This prompted us to define the structural requirements essential for this antiproliferative activity. Among all analogues synthesized in this study, compound 1o was the most promising, being 10-fold more potent than compound 1d. Its activity over a panel of nine tumoral cell lines was in the nanomolar range for all of the histological types tested, and surprisingly, the resistant KB-A1 cell line was also sensitive to this compound. Moreover, a flow cytometric study showed that L1210 cells treated by the most potent compounds were arrested in the G(2)/M phases of the cell cycle with a significant percentage of cells having reinitiated a cycle of DNA synthesis without cell division. This interesting pharmacological profile, resulting from inhibition of tubulin polymerization, encouraged us to perform preliminary in vivo studies that led to a new prodrug chemical approach.
    DOI:
    10.1021/jm030961z
点击查看最新优质反应信息

文献信息

  • Design, synthesis and antiproliferative activity of tripentones: A new series of antitubulin agents
    作者:Vincent Lisowski、Cécile Enguehard、Jean-Charles Lancelot、Daniel-Henri Caignard、Stéphanie Lambel、Stéphane Leonce、Alain Pierre、Ghanem Atassi、Pierre Renard、Sylvain Rault
    DOI:10.1016/s0960-894x(01)00403-6
    日期:2001.8
    Structure-activity relationship studies of a new series of tripentones (thieno[2.3-h]pyrrolizin-8-ones), led us to prepare several derivatives with antiproliferative activities. The most promising 3-(3-hydroxy-4-methoxyphenyl)thieno[2.3-b]pyrrolizin-8-one 20 (leukemia L1210. IC50= 15 nM) was shown to be a potent inhibitor of tubulin polymerization. (C) 2001 Elsevier Science Ltd. All rights reserved.
  • Dérivés de 8H-(2,3-b)-pyrrolizine-8-one, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
    申请人:LES LABORATOIRES SERVIER
    公开号:EP0982308B1
    公开(公告)日:2003-02-26
  • US6071945A
    申请人:——
    公开号:US6071945A
    公开(公告)日:2000-06-06
  • Design, Synthesis, and Evaluation of Novel Thienopyrrolizinones as Antitubulin Agents
    作者:Vincent Lisowski、Stéphane Léonce、Laurence Kraus-Berthier、Jana Sopková-de Oliveira Santos、Alain Pierré、Ghanem Atassi、Daniel-Henri Caignard、Pierre Renard、Sylvain Rault
    DOI:10.1021/jm030961z
    日期:2004.3.1
    Herein, we describe the structure-activity relationship study of a new 3-aryl-8H-thieno[2,3-b]pyrrolizin-8-one series of antitubulin agents. The pharmacological results from the National Cancer Institute in vitro human disease oriented tumor cell line screening allowed us to identify compound 1d (NSC 676693) as a very efficient antitumoral drug in all cancer cell lines tested. This prompted us to define the structural requirements essential for this antiproliferative activity. Among all analogues synthesized in this study, compound 1o was the most promising, being 10-fold more potent than compound 1d. Its activity over a panel of nine tumoral cell lines was in the nanomolar range for all of the histological types tested, and surprisingly, the resistant KB-A1 cell line was also sensitive to this compound. Moreover, a flow cytometric study showed that L1210 cells treated by the most potent compounds were arrested in the G(2)/M phases of the cell cycle with a significant percentage of cells having reinitiated a cycle of DNA synthesis without cell division. This interesting pharmacological profile, resulting from inhibition of tubulin polymerization, encouraged us to perform preliminary in vivo studies that led to a new prodrug chemical approach.
  • 8H-thieno-[2,3-b]pyrrolizin-8-one compounds
    申请人:Adir et Compagnie
    公开号:US06071945A1
    公开(公告)日:2000-06-06
    A compound selected from those of formula (I): ##STR1## wherein: R.sub.1 represents hydrogen, halogen, alkyl, nitro, hydroxy, alkoxy, trihaloalkyl, trihaloalkoxy or optionally substituted amino, R.sub.2 represents optionally substituted aryl or heteroaryl, R.sub.3 represents hydrogen, halogen, alkyl, nitro, hydroxy, alkoxy, trihaloalkyl, trihaloalkoxy or optionally substituted amino, their isomers and addition pharmaceutically-acceptable acid or base salts thereof and medicinal products containing the same are useful in the treatment of cancer.
    公式(I)中选择的化合物:##STR1## 其中:R.sub.1代表氢,卤素,烷基,硝基,羟基,烷氧基,三卤代烷基,三卤代烷氧基或可选取代氨基,R.sub.2代表可选取代的芳基或杂环基,R.sub.3代表氢,卤素,烷基,硝基,羟基,烷氧基,三卤代烷基,三卤代烷氧基或可选取代氨基,它们的异构体和药学上可接受的酸或碱盐以及含有它们的药物制品在癌症治疗中有用。
查看更多